Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Core Insights - Annovis Bio, Inc. is advancing its investigational oral therapy, buntanetap, for neurodegenerative diseases, achieving significant milestones in clinical development during 2025 [1][2] Clinical Progress - In 2025, Annovis initiated a pivotal Phase 3 clinical trial for early Alzheimer's disease (AD) and launched an open-label extension (OLE) study for Parkinson's disease (PD) [2][3] - The Phase 3 study for AD began in February 2025, with the first participants reaching a 6-month milestone by October 2025, showing potential disease-modifying activity through reductions in neurotoxic biomarkers [7] - As of March 2026, 65% of the target participant population for the Phase 3 AD trial has been enrolled across 83 clinical sites in the U.S. [7] - New biomarker data indicated that buntanetap improved cognition in PD patients and reduced amyloid and tau pathology [7] Business Highlights - Annovis transferred all patents to a new crystal form of buntanetap in August 2025, extending intellectual property protection until 2047 [11] - The company held 40 granted patents and 48 patent applications as of year-end 2025, with most patents approved in major global markets [11] - Annovis participated in key scientific conferences and investor events throughout 2025, enhancing its visibility in the biopharma sector [11] Financial Results - Research and development expenses for 2025 were $25.2 million, up from $20.0 million in 2024, while general and administrative expenses decreased to $4.5 million from $6.7 million [10][19] - Annovis reported a net loss of $28.9 million for 2025, with a basic and diluted net loss per share of $1.40, compared to a net loss of $24.6 million in 2024 [10][19] - Cash and cash equivalents increased to $19.5 million as of December 31, 2025, compared to $10.6 million in 2024, providing funding into the third quarter of 2026 [10][19]